Author of

• 25938

  +

  P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26860

    +

    P2.01-61 - Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy. (ID 13880)

    16:45 - 18:00  |  Presenting Author(s): Stephanie Labomascus
    • Abstract
    • Slides

    Background
    

    Cachexia has been associated with inferior outcomes for patients with stage III/IV NSCLC (aNSCLC). This study evaluates the potential relationship between baseline and longitudinal body mass index (BMI) with progression free survival (PFS) and overall survival (OS) in aNSCLC patients on nivolumab or pembrolizumab.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Patients with aNSCLC who received at least once cycle of nivolumab or pembrolizumab between January 2015 and January 2017 were identified in our pharmacy database. Patient demographics, longitudinal BMIs, treatment start date, date of progression, and last follow-up were recorded. OS and PFS were assessed by log-rank tests and Cox proportional hazard analysis. Time-dependent Cox model based analyses were used to assess the association between time dependent BMIs.

    4c3880bb027f159e801041b1021e88e8 Result
    

    The study included 162 aNSCLC patients. Median age 68 yrs, male/female 40.1%/59.9%. BMI values were obtained longitudinally at baseline, 6 wks, and 12 wks. Median BMI: baseline 24.69, at 6 wks 24.75, and at 12 wks 24.89. Median change in BMI: baseline to 6 wks = -0.50 (range: -5.79 to +2.92), baseline to 12 wks = -0.33 (range: -6.52 to +3.41), and 6 wks to 12 wks = -0.21 (range: -4.56 to +2.73). Hazard ratios for change in BMI with OS: baseline to 6 wks HR 0.7198 (p=0.0010), baseline to 12 wks HR 0.8703 (p=0.0553), and 6 wks to 12 wks HR 0.8284 (p=0.0668).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Change in BMI over time is associated with OS in aNSCLC patients treated with nivolumab or pembrolizumab. Although decrease in BMI may simply be a prognostic marker for treatment with immune checkpoint inhibitors, it is possible that understanding potential relationships between cachexia and the immune system may be useful in developing strategies to improve response to immunotherapy.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.